background: The effects of oral contraceptives (OCs) on mental health are not clear, and no study has been focused on the effects of the levonorgestrel-releasing intrauterine system (LNG-IUS) on mental health. The aim of this study was to analyse the association between the use of OCs and the LNG-IUS and psychological well-being and psychopathology. ) ; some of the analyses were extended to include the younger age group (18-to 54-year-old sample; n ¼ 3223).
Introduction
The rates of many psychiatric disorders differ according to gender, with mood disorders [especially major depressive disorder (MDD)] (Kuehner, 2003) and anxiety disorders (Pigott, 1999; Seedat et al., 2009 ) being more common in women than in men. Therefore, the possibility of a significant relationship between mental health and contraception merits investigation.
Contraception is of great importance as regards women's reproductive life from both a (psycho-) social-and a (mental) health-related point of view. A great amount of research has been focused on side effects and beneficial effects of hormonal contraceptives, with the general conclusion that oral contraceptive (OC) use is associated with several health benefits, such as lower risks of endometriosis, and endometrial and ovarian carcinoma (Maia and Casoy, 2008; Braem et al., 2010) . However, little is known about the effects of hormonal birth control on mental health, and the findings reported in the literature are contradictory and inconsistent. In an earlier study by Herzberg et al. (1971) , it was reported that mean depression scores decreased in women continuing the use of an intrauterine device or an OC, while they increased in women stopping or changing OCs. More recent studies have shown no significant association between OC use and depression (Duke et al., 2007; O'Connell et al., 2007) . Rapkin et al. (2006a) found no relationship between OC-induced reduction in the concentrations of circulating neuroactive steroids and mood or anxiety symptoms in healthy women. Nevertheless, depression is often mentioned as a possible side effect of OCs as well as of hormonal contraceptive implants or injections, and women continue to report depression and other mood changes as common reasons for discontinuation of OCs (Oinonen and Mazmanian, 2002) . It has been suggested that mood and affective changes such as OC side effects may occur in a subgroup of vulnerable women (Oinonen and Mazmanian, 2002; Rapkin et al., 2006a) . It has also been claimed that specific personality traits, i.e. somatic anxiety and stress susceptibility, are more common among women who present mood complaints as a side effect of OCs (Borgströ m et al., 2008) .
Inconsistent results also come from the research concerning depressive side effects of hormonal injectable contraceptives [e.g. depot-medroxyprogesterone acetate (depot-MPA)] and hormonal contraceptive implants (e.g. levonorgestrel implant). Westhoff et al. (1998a,b) did not find any increase in depressive symptoms among women using depot-MPA or hormonal implants, and no symptomworsening in women with pre-existing depression. Conversely, other authors (Archer et al., 1997; Civic et al., 2000) have reported an association between depot-MPA use and depressive symptoms. Even though there are these inconsistencies, mood changes are reported as possible side effects of contraceptive injections and implants.
Information concerning the possible side effects of the levonorgestrel-releasing intrauterine system (LNG-IUS) on mental health is even scantier. Since its introduction in the 1990s, it has been increasingly used in contraception as well as in the treatment of heavy menstrual bleeding worldwide. Studies concerning acceptability and the reasons for and rates of discontinuation indicate bleeding problems, amenorrhoea and hormonal adverse effects as possible consequences of use of the LNG-IUS (Rö nnerdag and Odlind, 1999; Inki, 2007) . Mild and rare hormonal side effects have been reported, such as nausea, breast tenderness, headache, skin problems, mood changes and nervousness (Luukkainen, 1991; Luukkainen et al., 1990 Luukkainen et al., , 2001 . However, to the best of our knowledge, no study has been focused on the effects of the LNG-IUS on mental health.
The effects of gonadal steroids on the central nervous system are well characterized (Rubinow et al., 1998; Genazzani et al., 2007; Pluchino et al., 2009) . In brief, estrogens are known to contribute to the development of brain gender difference, as well as to regulate many neurotransmitter systems (serotonin, noradrenalin and dopamine). Similarly, progestins participate in the control of opioidergic, serotoninergic and cholinergic systems. Albeit at low systemic levels, the LNG released by the LNG-IUS is rapidly absorbed into the general circulation and may cross the blood-brain barrier. It is thus possible that some neuropsychological effects occur during the use of the LNG-IUS.
The aim of our research was to study the potential relationship(s) between hormonal contraceptives versus depressive symptoms, psychological well-being and risk of psychiatric diagnoses. We specifically focused on two widely used contraceptive methods, i.e. OCs and the LNG-IUS.
Materials and Methods
The data analysed were collected in the Health 2000 Survey, a crosssectional, nation-wide, population-based study carried out in Finland during 2000 and 2001 (www.terveys2000.fi). The stratified and clustered sampling procedure allowed us to obtain a representative sample (n ¼ 8028) of the general population aged 30 years and older (Heistaro, 2008) . Data collection consisted of a home interview followed by a clinical health examination; a total of four self-administered questionnaires was also used. A modified version of the Beck Depression Inventory (BDI) (Raitasalo, 1995) and the General Health Questionnaire-12 (GHQ-12) were included in the self-administered questionnaires. In connection with the health examination, the Composite International Diagnostic Interview (CIDI), a structured mental health interview, was carried out to assess mental health in the previous 12 months.
A separate random sample of those aged 18-29 years (n ¼ 1894) was taken. For these young adults, data collection involved a home interview and two self-reported questionnaires (including the GHQ-12 questionnaire).
Approval for the survey was obtained from the National Public Health Institute's Ethics Committee (1999) and from the Ethics Committee for Research in Epidemiology and Public Health at the Hospital District of Helsinki and Uusimaa (2000) . Written informed consent was obtained from all participants.
Reproductive health
Information on reproductive health characteristics of the subjects was collected systematically during the interviews. The questions included information on the menstrual cycle, pregnancies, infertility, the use of contraception and hormonal replacement therapy. The current use of hormonal contraceptives was assessed in women aged 30 -54 years ('Do you take contraceptive pills at the moment?' and 'For birth-control, are you using a hormonal intrauterine device at the moment?'). The length of time of hormonal birth control use ('For how many years altogether have you been taking contraceptive pills/a hormonal intrauterine device?') was also specified, as well as the current brand of OC.
The current use of hormonal contraception and its duration, as well as the current brand of OC, were also assessed among young women (aged 18 -29 years), using the same questions.
The number of living children was assessed via the question 'How many living children do you have at the moment, including adopted children, children whose foster parent you are and other "non-biological children"?'. The experience of having given birth was assessed via the questions 'How many children have you delivered?' and 'How many were born alive?'.
Bleeding patterns were also investigated in the 30-to 54-year-old group, via the question 'Do you have periods nowadays: regularly, irregularly or none?'.
Mental health
Psychological well-being was assessed by using the 12-item GHQ, a broadly used questionnaire introduced by Goldberg (1972) to evaluate the common mental state, with particular attention to the areas of depression and anxiety. The GHQ gives a view of recent general mental health (in the past 4 weeks). The presence and severity of depressive symptoms in the previous 2 weeks were assessed via a modified version of the 21-item BDI (Raitasalo, 1995) , a reliable and commonly used selfreported inventory validated by Beck et al. (1961) to assess depression, inquiring specifically into depressive, cognitive and somatic symptoms. BDI and GHQ total scores were considered only for the cases with a valid answer for each item; each BDI and GHQ item score was calculated for all the participants with a valid answer for that item.
At the end of the health examination, a structured diagnostic interview (CIDI) developed by the World Health Organization was carried out: the Munich computerized version of the CIDI (Wittchen et al., 1998) . The CIDI interview was administered by trained interviewers, allowing them to assess the presence, onset and recency of psychiatric disorders within the 12 months preceding the interview. For the purpose of this study, we focused on MDD, dysthymic disorder, any anxiety disorder, alcohol abuse and dependence. 'Any current psychiatric diagnosis' was defined as meeting the criteria for at least one full diagnosis in the last 12 months (excluding cases with missing data at one or more of the diagnoses inquired about).
The GHQ was included as regards the young adults, while data from the BDI questionnaire and the CIDI were not available for this cohort. However, lifetime history of psychiatric diagnoses (psychosis, depression, anxiety, substance use or other) was assessed among the young adults (as well as among 30 year and older women) in connection with the home interview ('Has a doctor ever diagnosed psychological or mental illness?').
Statistical analyses
Bivariate analyses were performed to study the difference between groups, using the current use of OCs and current use of the LNG-IUS as grouping variables. The x 2 test was used to compare frequencies in tables and Fisher's exact test was selected when expected frequencies were less than five. For continuous variables, comparison of means was carried out using Student's t-test. A P-value ,0.05 was considered significant. The existence of partial correlations (age as a controlling variable) between both BDI scores and GHQ scores, and current use of OCs and duration, and current use of the LNG-IUS and duration were investigated. We also tested for the existence of partial correlations with each BDI item and with each GHQ item. Partial correlation between current use of OCs and duration, versus GHQ data were also investigated among women aged 18 -54 years.
Multivariable analysis was performed, using linear regression models, to identify the predictors that had a significant association with BDI score (and each BDI item score). Age, professional status, marital status, educational level, bleeding pattern (regular, irregular or none) and current psychiatric diagnosis (as assessed via the CIDI) were entered in all the models as predictors. Use of OCs or the LNG-IUS, and the length of time of use were added separately in each model. The association between OC use (as well as its duration) and GHQ data was tested on the extended sample (age 18 -54 years), using self-reported lifetime psychiatric diagnoses rather than current CIDI psychiatric diagnoses as controlling variables in the linear regression models. The association between the LNG-IUS use and GHQ data was investigated only among the 30 -54 years sample because of the small number of young women using the LNG-IUS (n ¼ 8).
Logistic regression was performed to identify those predictors (among age, professional status, marital status, educational level, bleeding pattern, use of OCs, duration of OC use, use of the LNG-IUS and duration of its use) that had a statistically significant association with current psychiatric diagnosis (CIDI).
The results in the linear and logistic models were adjusted separately for the number of living children and the experience of having given birth.
Lastly, the effects of second-generation (i.e. those containing levonorgestrel, norgestimate or cyprotereone acetate) versus the third-generation (those containing desogestrel or gestodene) combined OCs (COCs) were tested in three additional (two linear and one logistic) regression models [independent variables: age, professional status, marital status, educational level, bleeding pattern (when available), psychiatric diagnosis and generation of COC].
Cases with missing data concerning one or more variables were omitted from the analyses.
Descriptive and multivariable analyses were performed using SPSS/ PASW software (version 18.0) (SPSS Inc., Chicago, IL, USA).
Results

Characteristics of the participants
The initial sample consisted of 2310 women aged 30 -54 years (mean age 42.2 years; SD 7.2). The response rates as regards CIDI, BDI and GHQ-12 data were, respectively, 80.5% (n ¼ 1859), 86.0% (n ¼ 1987) and 87.5% (n ¼ 2022).
The young adults' sample consisted of 913 women (mean age 23.4 years; SD 3.5). Reliable GHQ-12 questionnaire data were available from 677 young women (response rate 74.2%).
Socio-demographic characteristics of the study participants are reported in Table I .
Oral contraceptives
Of the 2310 women aged 30-54 years, 181 (9.5%; data missing for 410) were using OCs for birth control at the time of the interview; 93 (23.5%) were aged 30-34 years, 53 (13.2%) were aged 35-39 years, 23 (6.2%) were aged 40-44 years, 10 (2.6%) were aged 45 - 
Hormonal contraception and mental health 49 years and 2 (1.1%) were aged 50-54 years. Nine women were using a progestin-only-pill (POP), 88 a second-generation COC and 77 a third-generation COC (missing data for 7). Socio-demographic features and descriptive analyses are reported in Table II . The mean duration of current OC use was 11.6 years (SD 5.3; range 0.5 -30). Moreover, 332 of the young women (43.7%; missing data for 154) reported using OCs (mean duration 4.9 years; SD 3.4; range 0.5 -19). Eight of them were using a POP, 62 a second-generation COC and 259 a third-generation COC (missing data for 3). When performing partial correlations (controlling for age) between current OC use and duration versus BDI total scores, no significant results were found. A negative correlation was found between duration of current OC use and BDI items 'dissatisfaction' (r ¼ 20.214; P , 0.01), 'irritability' (r ¼ 20.161; P , 0.05), 'lost interest in people' (r ¼ 20.193; P , 0.05), 'earlier waking' (r ¼ 20.160; P , 0.05) and 'lost interest in sex' (r ¼ 20.185; P , 0.05), while 'worries about one's health' significantly directly correlated with duration of current OC use (r ¼ 0.192; P , 0.05).
As regards partial correlations with GHQ-12 data in the extended age group (i.e. women aged 18-54 years), no significant results were found.
In linear regression analysis (age, marital status, professional status, educational level, bleeding pattern, recent psychiatric diagnosis and use of OCs as independent variables), no significant association with BDI total score was found. The current use of OCs was inversely associated only with the BDI item 'feelings of worthlessness' (Table III) . The results did not change when adjusted for number of living children or for having given birth.
In a model where current OC use was replaced with duration of OC use, the latter was significantly inversely associated with some of the BDI items ('feelings of dissatisfaction', 'irritability', 'lost interest in people', 'earlier waking' and 'lost interest in sex'), and directly associated with the item 'worries about one's health'. The results did not change when controlling for number of living children; when controlling for having given birth, only the association with 'irritability' was no longer significant. In multiple logistic regression analyses, no significant association was found between current OC use and any current psychiatric diagnosis. Conversely, the duration of current OC use was significantly associated with a higher risk of 'alcohol dependence'. When adjusting for number of living children, and for having given birth, duration of current OC use was also inversely associated with a diagnosis of MDD [odds ratio (OR) ¼ 0.882; 95% confidence interval (CI) ¼ 0.781-0.996; P , 0.05; and OR ¼ 0.878; 95% CI ¼ 0.777-0.992; P , 0.05, respectively].
The associations between current OC use and duration of OC use versus GHQ total score in the age group 18-54 years were tested in two other models of linear regression (controlled for age, marital status, professional status, educational level and lifetime self-reported psychiatric diagnosis) (Table III) . No significant results were found, even after controlling for the number of living children, and for having given birth.
Three additional regression models were used to test whether thirdversus second-generation COCs differently affect mental health and psychological well-being (age, marital status, professional status, educational level, lifetime self-reported psychiatric diagnosis/CIDI diagnosis and generation of COC as independent variables). The only significant association found was with the GHQ item 'impaired decision-making' (B ¼ 20.120; 95% CI ¼ 20.209 to 20.031; P , 0.01), in favour of third-generation pills. Because of the limited number of POP users, it was not possible to test the effects of POPs versus COCs.
The LNG-IUS
At the time of the interview, 212 women (11.2%; data missing for 410) aged 30 -54 years were using the LNG-IUS for birth control: 25 (6.3%) aged 30 -34 years, 56 (14.0%) aged 35-39 years, 48 (13.0%) aged 40 -44 years, 54 (14.0%) aged 45 -49 years and 29 (8.4%) aged 50 -54 years. The mean duration of LNG-IUS use was 5.1 years (SD 3.7; range 0.5-20). Socio-demographic features and descriptive analyses are reported in Table II. Significant negative correlations (controlling for age) were found between the current use of the LNG-IUS and the BDI total score (r ¼ 20.054; P , 0.05), and BDI items 'future hopelessness' (r ¼ 20.067; P , 0.01), 'suicidal ideation' (r ¼ 20.055; P , 0.05), 'earlier waking' (r ¼ 20.065; P , 0.01) and 'lost weight' (r ¼ 20.050; P , 0.05). No significant correlation was found between current LNG-IUS use and GHQ total score or any of the GHQ items, or with any current psychiatric diagnosis. The duration of LNG-IUS use was inversely correlated with the GHQ items 'strain' (r ¼ 20.177; P , 0.05) and 'feelings of depression' (r ¼ 20.144; P , 0.05).
In linear regression analysis (age, marital status, professional status, educational level, recent psychiatric diagnosis, pattern of bleeding and current use of the LNG-IUS as independent variables), statistically significant inverse associations were found between current use of the LNG-IUS and BDI 'total score', BDI 'earlier waking' (both maintained even after adjusting for number of living children, and for having given birth) and GHQ 'impaired concentration' (not maintained when controlling for number of living children, or for having given birth). When LNG-IUS use was replaced with duration of current LNG-IUS use, the latter was significantly inversely associated with the item strain of the GHQ-12. There were no other significant findings. In multiple logistic regression analyses, there were still no significant associations to be found between LNG-IUS use or its duration, and any current psychiatric diagnosis (Table IV) .
The association with the GHQ item strain was maintained when controlling for having given birth as well as for number of living children.
Discussion
The preliminary findings reported earlier suggest a relationship between the use of hormonal contraception and mental health. In particular, the current use of an OC seems to be only marginally associated with mood: the longer the duration of current OC use, the lower the score at some BDI items, and the lower the risk of MDD after controlling for possible confounding factors. In contrast, we found only a minimal association between mood and current use of the LNG-IUS (and its duration).
Strengths and limitations of the study
This study has some methodological shortcomings. Firstly, the studied groups (e.g. users versus non-users) are constituted by choice rather than chance. It is plausible that some of the factors leading to the choice whether to use or not a hormonal contraception (mostly relying on the woman's own decision or on the health care provider) have an influence on the results. Anyway, we were able to control our findings for some of those possible confounding factors (i.e. marital status, education, number of children, bleeding pattern). Additionally, this is a cross-sectional study with partly retrospective data collection. This may lead to recall bias as regards some variables, such as the duration of contraceptive use. Moreover, the lack of information about mental status preceding the contraceptive use prevented us from establishing a temporal relationship between contraceptive use and the onset of psychiatric symptoms. In addition, the results concerning the duration of birth control may have been biased by the fact that all earlier usage periods were included in the variable. Another limitation arises from the self-reported quality of mood and psychological well-being assessment. Nevertheless, the validity and reliability of the BDI and GHQ scales have been widely demonstrated (Goldberg et al., 1976; Beck et al., 1988) . Furthermore, a structured interview administered by trained nurses was used to assess the presence of a current psychiatric diagnosis.
The analyses concerning the young women (18-29 years) are limited because of the lack of BDI and CIDI data. Analyses concerning the association between OCs and GHQ data were carried out on a larger and more representative sample (18-54 years), but we could not control for the presence of current psychiatric diagnoses. Nevertheless, we could control for the effect of a self-reported lifetime psychiatric diagnosis. Lastly, the retrospective design of the study precludes any causal conclusions.
Strengths of this study include the nation-wide, population-based nature of the sample and the good response rate: relatively good generalization of the results is thereby possible.
Oral contraceptives
The relationship between OCs and emotional liability, mood changes (particularly on the depressive side) and anxiety has been studied previously. However, the results have been inconsistent. Although most of the evidence shows that there may be an increased risk of experiencing depressive symptoms only in a subset of vulnerable women, mood changes are still reported as possible side effects of oral contraception. The putative mechanisms by which OCs may influence mood include suppression of some neuroactive steroids (e.g. metabolites of progesterone: allopregnanolone, and allotetrahydrodeoxycorticosterone), which in turn affects the expression and activity of gammaaminobutiryc acid A receptors (Oinonen and Mazmanian, 2002; Rapkin et al., 2006a,b) and reduced levels of free testosterone (Graham et al., 2007) .
Our data show that women currently taking OCs had a lower although not significant BDI total score in comparison with women who were not taking them. Associations with the BDI items were also mostly negative (or only slightly positive), although non-significant. When checking the risk of psychiatric diagnosis, no significant association was found. We thus conclude that current OC use has no significant detrimental effect on mood. By contrast, it may have some favourable effects.
The lack of association between current OC use and depressive symptoms or disorders is consistent with recent results reported in the literature. In a randomized placebo-controlled trial, O'Connell et al. (2007) found no difference in depressive symptoms between adolescent girls taking OCs and controls. Rather, they found an improvement in depressive symptomatology over time, equally in OC-and placebo-users, even when restricting the analysis to a high- risk group (i.e. women with higher depressive scores at baseline). Similarly, Maes et al. (1992) found no mood difference between OC-users and non-users. Duke et al. (2007) also found no significant association between OC use and depression.
It has been shown that the use of oral hormonal contraception directly decreases the concentrations of some neuroactive steroids and their precursors. However, this does not lead to depressive outcomes in psychologically healthy women, although it is not possible to rule out the fact that it may affect mood in a subgroup of predisposed women (Rapkin et al., 2006a) . This is partly consistent with the results of two recent studies (Borgströ m et al., 2008; Segebladh et al., 2009 ). In the first study, the investigators found that depression-related personality traits (somatic anxiety and stress susceptibility) were more likely in women who complained of mood side effects of OCs. Similarly, in the second study, a higher prevalence of depressive and anxiety disorders was reported among women with mood side effects of current or past OC use. This could mean that women with specific depressive personality traits or with pre-existing vulnerability to mood disorders are more likely to complain of emotional side effects of OCs (Borgströ m et al., 2008; Segebladh et al., 2009) . It is therefore possible that the higher scores (even though not significant) in the GHQ and CIDI assessments found in our study also somehow reflect a subset of vulnerable women experiencing psychological distress not severe enough to reach significance at evaluation.
Since our study had a cross-sectional retrospective design, we were not able to assess any temporal relation between mood symptom onset and past OC use/discontinuation. Therefore, it is possible that the non-users group includes a proportion of women that has discontinued contraception (or switched to another method) because of side effects, including, at least in a subset of vulnerable women, depression or mood changes. This may have partly biased our findings of no detrimental effect of OC use on mood.
Moreover, according to our results, it seems that the duration of current use is associated with beneficial effects on mood, with significantly lower scores in connection with many BDI items and a lower risk of MDD (only after controlling for possible confounding factors). This is in line with the findings of Duke et al. (2007) . Because of the longitudinal design of their study, they also analysed the association between depressive symptoms and duration of OC use, reporting an inverse relationship (i.e. the proportion of women with depressive symptoms declined with the number of years of OC use) (Duke et al., 2007) .
It is worth remembering here that inconsistencies among the studies on OC effects may also be due to differences in the compounds (e.g. older-generation contraceptives, containing higher dosages and different types of estrogens and progestin, versus newer pills; or combined pills versus POPs). Nevertheless, our analyses showed no noteworthy effects when comparing second-and third-generation COCs.
Socio-demographic factors are also known to influence the contraceptive choice, with better educated women using contraception more frequently than less educated women (La Vecchia et al., 1986; Parazzini et al., 1996; Koponen and Luoto, 2004; Krings et al., 2008) . Also, contraception use is less frequent among unmarried than married, divorced or widowed women (La Vecchia et al., 1986; Parazzini et al., 1996) ; similarly, women who have new or multiple sexual partners, i.e. women who probably are not in a long-term relationship, are less likely to use any contraception (Raine et al., 2003; Krings et al., 2008) . Another factor that needs to be taken into account is the possible influence of menstrual irregularity on contraceptive choice as well as on mood and psychological well-being. Indeed, when analysing the effect of menstrual irregularity on this same data set, we found that women reporting menstrual irregularity or no cycles scored significantly worse at the BDI scale than women reporting regular flows (Toffol et al., unpublished data) . Similarly, Bisaga et al. (2002) reported an association between irregular cycles and depressive symptoms among high school girls. Conversely, the presence of menstrual irregularity may affect the decision whether to use or not a hormonal contraception, as well as the choice of the contraceptive type itself. Nevertheless, our results did not significantly change when controlling for all the above-mentioned confounding factors.
Lastly, the duration of current OC use was significantly related to alcohol dependence in our study. The question of whether or not sex steroids/hormonal contraceptives influence ethanol metabolism is still controversial (Warnet et al., 1984; King and Hunter, 2005) . Anyway, it is possible that our finding of an association between duration of OC use and alcohol dependence is a result of related confounding (e.g. psychosocial) factors. Indeed, it is possible that women with life-style factors associated with alcohol dependence (e.g. sexually risky behaviour or multiple partners) have been using (or have been advised to use) an effective contraceptive method (e.g. an OC) for a relatively long time. Also, the results may have been biased by the cross-sectional design of the study, which prevents any temporal relationship between mental status and contraceptive use. Hence, we cannot rule out the possibility that women with mental health problems or alcohol dependence have themselves chosen or have been advised to use the most effective methods of contraception (i.e. OCs and the LNG-IUS).
The LNG-IUS
To the best of our knowledge, this is the first study in which the relationship between mental health and use of the LNG-IUS has been directly addressed. Even though the circulating concentrations of levonorgestrel are low in women using the LNG-IUS, the LNG released is rapidly absorbed into the systemic circulation and is detectable in plasma 15 min after insertion of the device (Luukkainen, 1991) . It is therefore not surprising that some women experience hormonal side effects, the most commonly reported ones being headache, swelling, breast tenderness and skin problems. Nevertheless, these effects are relatively rare, transient and mostly self-limiting. Gonadal hormones may affect mood and psychological disposition, leading to changes in state-of-mind, emotional liability and anxiety in vulnerable women (Rubinow and Schmidt, 1995; Rubinow et al., 1998) . Our findings suggest that women currently using the LNG-IUS are not more depressed or in a worse psychological condition than women not using it. Conversely, the associations with most of the BDI and GHQ items were negative, although not significant. However, significant negative associations with the BDI total score and with the item 'earlier waking' were found. The duration of current use also had only a marginal association with mood and psychological wellbeing. Most of the studies available in the literature report good effectiveness and high satisfaction rates (around 90%) among LNG-IUS-users, with improved quality of life and psychological wellbeing (Skrzypulec and Drosdzol, 2008) . Nevertheless, some investigators have reported only a 50% rate of satisfaction, with the most commonly reported reasons for discontinuation of use of the LNG-IUS being bleeding, progestogenic adverse effects and abdominal pain (Daud and Ewies, 2008; Ewies, 2009 ). The present data suggest that the LNG-IUS per se has a minimal effect, if any, on mental health.
Conclusions
The study findings are in keeping with the notion of an influence of hormonal birth control methods on mental health, particularly as regards mood symptoms and disorders. Although the duration of current use of hormonal contraception (especially OCs) may have some beneficial effects on mood (symptoms and disorders), the longer this duration, the greater the association with a diagnosis of alcohol dependence. Further research is needed to better understand these associations, in particular as regards the hormonal effects of the LNG-IUS.
